Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc
AGNPF
Primary Symbol:
C.AGN
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 11, 2022 11:29am
Moreau misses/messaging/mark for the DMT stroke program.
Roth Capital Doubles Down on Cybin After DMT Acquisition Earlier this week we reported on Cybin acquiring a DMT Clinical Study from Entheon Biomedical. The study is the largest Phase 1
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 11, 2022 10:09am
ALGERNAUTS BLOG
investorshub.advfn.com/boards/read_msg.aspx?message_id=169119648 Who else is going to tell bagholders story...YOU? Also, the Stockhouse platform sucks royally.
Fintech Select LTD. Publishes Results for Fiscal Year 2023
posted May 01, 2024 9:00am by
Fintech Select Ltd.
-
|
Under the leadership of Fintech Select's management, the Company achieved a significant milestone in revenue generation, reaching $3,822,182 for fiscal year 2023, compared to $2,587,867 in 2022. Management is confident this 47% increase on a year-over-year basis ...read more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on Jun 06, 2022 10:24pm
Ummm...
Robert Claypool @hackwrench1
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on May 31, 2022 7:14pm
Algernauts @ Algernauts.com
Algernon Pharma
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on May 28, 2022 1:33pm
Prime Domain Name
Open Question: Go to Page 3 of Algernon Pharmaceuticals - Financial Statements for quarter ended February 28, 2022: https://webfiles.thecse.com/AlgernonFEB2822FS.pdf? AqxYNIv1
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on May 27, 2022 12:51pm
RE:RE:RE:Down Trade
Yeah...they're all wearing $HORT$ under the table.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Comment by
nodaytrader
on May 27, 2022 12:40am
RE:RE:Down Trade
Then the grown-ups will be in charge. Can't wait!
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Comment by
C10H12N2
on May 26, 2022 5:16pm
RE:Down Trade
You'll be pulling out your eyebrows once AGNP uplists to NASDAQ.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on May 26, 2022 3:52pm
Down Trade
Zero volume traded for four hours - then one minimum trade driving the price down by $0,45. (7.5%) Could we call this the masturbatory school of investing?
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on May 26, 2022 9:17am
21st Century Link
https://algernonpharma.com/
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on May 21, 2022 3:39am
COVID Breathalyzer
UNT built a breathalyzer that detects COVID. A Frisco company just got FDA approval to put it to work. How does the device work, exactly? Verbeck explained that the technology mimics the carbon filter
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on May 18, 2022 6:32pm
Truth: Deal With It
https://investorshub.advfn.com/boards/RequestReview.asp?msg_id=168897796
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on May 17, 2022 9:32am
Here They Go Again...Headed Over Another Steep Cliff
What kind of Phase 2 clinical trial does Algernon expect to conduct in Australia (AGAIN) where only 500 Thousand USD from the fire sale offering is allocated to conduct the combined IPF & Chronic
...more
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on May 12, 2022 9:22am
From 2.1M Shares Fully Diluted To 6.5M Shares Fully Diluted
Pure Insanity at the remote (no office location) company.
(13)
•••
C10H12N2
X
View Profile
View Bullboard History
Post by
C10H12N2
on May 12, 2022 1:13am
The Stock Is Down 90% Since Moreau Became CEO
And Falling. EOM
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company